

Gene & Cell Therapy

PartnerRe



PULSE + Plus[®] takes a client-centered approach to gene and cell therapy. We offer proven risk solutions dedicated to optimizing financial outcomes that fit our clients' risk appetite and unique coverage needs.

Key features of our robust offering:

- **Access to the top 4 cellular therapy networks:** Optum, Cigna LifeSOURCE, Emerging Therapy Solutions (ETS) and INTERLINK. ***PULSE + Plus***[®] will review contract options and recommend most advantageous therapy agreement, place the network contract for you and support resolving claims and payment issues.
- **Access to the leading gene therapy networks:** ETS and their Programs of Excellence and Optum's Preferred Provider Network.
- **Facilitate single case agreements**, if network contracts are not available.
- Access to our curated vendors who offer **physician review services** to validate treatment and medical necessity.
- Multiple resources and tools to support in the **identification of members most likely to receive a therapy**, allowing our clients to proactively identify and manage the risk.
- **Education** and guidance on best practices related to prior authorization processes and plan language.
- Regular updates to our clients and brokers about expanded indications for currently approved therapies, **pipeline updates** and anticipated FDA approvals, as well as expected costs.
- Our actuaries are available to provide **input on expected number and overall cost of high-cost therapies** for our client's population(s).
- **Bill review and negotiation**, even with a network contract in place.

Contact your dedicated **PULSE + Plus®** Clinical Consultant to see how our programs can work for you. Let us help you today to reduce costs tomorrow.



Missy Kveene, RN, PHN, MBA
VP, Managing Director **PULSE + Plus®**
+1 612 234 4918
missy.kveene@partnerre.com



Erin Dugan, RN, CCM
Senior Clinical Consultant
+1 612 234 4923
erin.dugan@partnerre.com



Meghann Rezabek, RN
Clinical Consultant
+1 612 234 4963
meghann.rezabek@partnerre.com



Johnelle Heitschmidt, RN
Clinical Consultant
+1 612 234 4965
johnelle.heitschmidt@partnerre.com



Victoria Buchanan, RN, CCM
Senior Clinical Consultant
+1 913 871 7202
victoria.buchanan@partnerre.com

Did you know?

- There are over 3,500 gene and cell therapies in development from preclinical through pre-registration stages.
- CAR-T pricing ranges from \$300K-\$600K+, before markup, which makes case rate methodology difficult to predict and price.
- Provider markup on CAR-T can range from 300-400%.
- Medicaid reimbursement varies from state-to-state and is evolving as more gene and cell therapies are entering the market.
- Biomarin announced that the FDA has accepted their application for Hemophilia A gene therapy with an estimated approval date of March 31, 2023.
- For 2023, we are monitoring the expected approvals for 11 gene therapies and 5 cell therapies.

www.partnerre.com/health